0000000000134669

AUTHOR

Ursula Creutzig

showing 4 related works from this author

Early deaths from childhood cancer in Germany 1980-2016

2020

Abstract Background Even though the survival of childhood cancer has improved over the last decades, there are still children dying shortly after diagnosis. The aim of the study is to add to understanding of the reasons for deaths shortly after date of diagnosis. Methods Using data of the population-based German Childhood Cancer Registry (cancer below 15 years of age diagnosed between 1980 and 2016), we compared characteristics of 671 children with cancer who died within 30 days of diagnosis to 53,649 patients with childhood cancer who survived longer. In addition to a descriptive analysis, we used logistic regression with multivariable fractional polynomials to describe the relationship be…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentEpidemiologyPopulationMedizinLower riskCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineRisk FactorsGermanyNeoplasmsEpidemiologyHumansMedicineRegistries030212 general & internal medicineChildeducationeducation.field_of_studyChildhood Cancer Registrybusiness.industryInfantCancerOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseConfidence intervalLeukemia Myeloid AcuteOncologyChild Preschool030220 oncology & carcinogenesisPopulation studyFemalebusiness
researchProduct

Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study

2019

Abstract Background With rising numbers of childhood cancer survivors, somatic and socioeconomic outcome as well as health-related quality of life (QoL) gain increasing relevance. Based on the first nationwide German Survey on Life Situation, State of Health, and Quality of Life of Childhood Cancer Survivors, the VIVE survey, we report the outcome of survivors of childhood brain tumors localized in the posterior fossa. Methods Two hundred seventy participants with a median follow-up period of 21.9 years completed a questionnaire on socioeconomic and somatic late effects as well as a standardized QoL questionnaire (European Organisation for Research and Treatment of Cancer QLQ-C30). Comparis…

Cancer ResearchState of healthHealth StatusPopulationCohort Studies03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesHumansMedicineSurvivorsChildeducationSocioeconomic statuseducation.field_of_studyBrain Neoplasmsbusiness.industryConfoundingEditorialsCancermedicine.diseasehumanitiesSocioeconomic FactorsOncology030220 oncology & carcinogenesisCohortQuality of LifeNeurology (clinical)businessPediatric Neuro-Oncology030217 neurology & neurosurgeryCohort studyDemography
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

2015

Abstract Background: Acute promyelocytic leukemia (APL) is a rare subtype of childhood acute myeloid leukemia (AML). Bleeding complications occur in 80% of patients at diagnosis and contribute to a higher incidence of early death (ED) in APL compared to other AML subtypes. However, estimates of ED in pediatric APL are imprecise and factors associated with ED in children with APL are unknown. Objectives: To determine the incidence and predictors of ED, defined as death within 60 days from presentation, in childhood APL. Methods: We conducted a retrospective international analysis of children diagnosed with APL between January 1993 and December 2013. The study included 236 patients from the I…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyChildhood Acute Myeloid LeukemiaRetrospective cohort studyCell BiologyHematologyOdds ratiomedicine.diseaseBiochemistryClinical trialmedicinebusinessBody mass indexLung allocation scoreBlood
researchProduct